Patents by Inventor Natalie Winblade Nairn
Natalie Winblade Nairn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
Patent number: 11866466Abstract: Peptide-immuno-oncology agent complexes (“peptide-I/O complexes”) that can home, target, migrate to, are directed to, are retained by, accumulate in, penetrate, or bind to the tumor microenvironment, tumor tissues, or cells or compartments or cytosol of cells thereof, or any combination thereof, are disclosed. Additionally disclosed are peptide-I/O complexes that can cross the blood-brain barrier. Pharmaceutical compositions and uses for peptide-I/O complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an immuno-oncology agent (“I/O”) to the tumor microenvironment. Targeted compositions of the disclosure can deliver peptide-I/O complexes to target regions, tissues, structures or cells targeted by the peptide.Type: GrantFiled: December 18, 2018Date of Patent: January 9, 2024Assignee: BLAZE BIOSCIENCE, INC.Inventors: Natalie Winblade Nairn, Julia Novak, Kenneth Grabstein, Dennis Miller, Greg T. Hermanson, Scott R. Presnell, Mark Stroud -
Publication number: 20230211000Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.Type: ApplicationFiled: August 15, 2022Publication date: July 6, 2023Inventors: Stacey J. Hansen, Claudia Jochheim, Dennis M. Miller, Natalie Winblade Nairn, Julia E. Novak, Mark R. Stroud, Valorie R. Wiss, Kelly Byrnes-Blake, Scott Presnell
-
Patent number: 11559580Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.Type: GrantFiled: August 23, 2021Date of Patent: January 24, 2023Assignee: BLAZE BIOSCIENCE, INC.Inventors: Stacey J. Hansen, Claudia Jochheim, Dennis M. Miller, Natalie Winblade Nairn, Julia E. Novak, Mark R. Stroud, Valorie R. Wiss, Kelly Byrnes-Blake, Scott Presnell
-
Patent number: 11331393Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptide-active agent conjugates are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the kidney. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.Type: GrantFiled: June 14, 2018Date of Patent: May 17, 2022Assignee: Blaze Bioscience, Inc.Inventors: Julia E. Novak, Natalie Winblade Nairn, Dennis M. Miller
-
Publication number: 20210260205Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.Type: ApplicationFiled: April 14, 2021Publication date: August 26, 2021Inventors: Julia E. Novak, Natalie Winblade Nairn, Dennis M. Miller, Scott Presnell, Claudia Jochheim, Mark Stroud
-
Publication number: 20210171589Abstract: Truncated, variant, or mutated peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for truncated or mutated peptides or truncated or mutated peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver truncated or mutated peptide or truncated, variant, or mutated peptides or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.Type: ApplicationFiled: March 15, 2019Publication date: June 10, 2021Inventors: Natalie Winblade NAIRN, Scott PRESNELL, Claudia JOCHHEIM, Mark STROUD
-
Patent number: 11013814Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.Type: GrantFiled: March 16, 2018Date of Patent: May 25, 2021Assignee: Blaze Bioscience, Inc.Inventors: Julia E. Novak, Natalie Winblade Nairn, Dennis M. Miller, Scott Presnell, Claudia Jochheim, Mark Stroud
-
TUMOR HOMING AND CELL PENETRATING PEPTIDE-IMMUNO-ONCOLOGY AGENT COMPLEXES AND METHODS OF USE THEREOF
Publication number: 20210130419Abstract: Peptide-immuno-oncology agent complexes (“peptide-I/O complexes”) that can home, target, migrate to, are directed to, are retained by, accumulate in, penetrate, or bind to the tumor microenvironment, tumor tissues, or cells or compartments or cytosol of cells thereof, or any combination thereof, are disclosed. Additionally disclosed are peptide-I/O complexes that can cross the blood-brain barrier. Pharmaceutical compositions and uses for peptide-I/O complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an immuno-oncology agent (“I/O”) to the tumor microenvironment. Targeted compositions of the disclosure can deliver peptide-I/O complexes to target regions, tissues, structures or cells targeted by the peptide.Type: ApplicationFiled: December 18, 2018Publication date: May 6, 2021Inventors: Natalie Winblade NAIRN, Julia NOVAK, Kenneth GRABSTEIN, Dennis MILLER, Greg T. HERMANSON, Scott R. PRESNELL, Mark STROUD -
Publication number: 20200262877Abstract: Disclosed herein are compositions and methods of use comprising peptides that bind to ion channels. Such peptides can function as active agents that target ion channels to inhibit or activate ion channels in a target tissue or cell type. In some embodiments, such peptides can be conjugated to another active agent or a detectable label.Type: ApplicationFiled: October 8, 2018Publication date: August 20, 2020Inventors: Christopher Mehlin, Natalie Winblade Nairn, Scott Ronald Presnell
-
Publication number: 20190375786Abstract: Peptides that are stable to denaturation and degradation by reducing agents, proteases, temperature, and low pH environments are disclosed. Pharmaceutical compositions and uses for peptides, peptide-active agent conjugates, and peptide-detectable agent conjugates comprising such peptides are also disclosed. Peptide compositions, peptide conjugate compositions, and pharmaceutical compositions can be formulated for various routes of delivery, such as oral delivery, and for deliver to various compartments of the body. Peptides of this disclosure are stable and display enhanced pharmacokinetics after such delivery.Type: ApplicationFiled: September 9, 2017Publication date: December 12, 2019Inventors: Emily June GIRARD, Colin CORRENTI, James OLSON, Natalie Winblade NAIRN, Mesfin Mulugeta GEWE, Christopher MEHLIN, Zachary CROOK, Roland STRONG, Scott Ronald PRESNELL
-
Patent number: 10202447Abstract: The invention relates inter alia to a bivalent, bispecific construct comprising an anti-IL-6 antibody, or derivative thereof, and an anti-IL-23 antibody, or derivative thereof and its use in therapy. The invention also relates to useful anti-IL-6 antibodies and anti-IL-23 antibodies.Type: GrantFiled: October 19, 2015Date of Patent: February 12, 2019Assignee: MedImmune LimitedInventors: Kenneth Grabstein, William Brady, Gordon King, Natalie Winblade Nairn, Kurt David Shanebeck, Paul Heffner Slagle, Kenneth Christopher Thornton, Michael Peter Vanbrunt, Andrea Wang, Hengyu Xu
-
Publication number: 20160194391Abstract: The invention relates inter alia to a bivalent, bispecific construct comprising an anti-IL-6 antibody, or derivative thereof, and an anti-IL-23 antibody, or derivative thereof and its use in therapy. The invention also relates to useful anti-IL-6 and anti-IL-23 antibodies.Type: ApplicationFiled: October 19, 2015Publication date: July 7, 2016Inventors: Kenneth Grabstein, William Brady, Gordon King, Natalie Winblade Nairn, Kurt David Shanebeck, Paul Heffner Slagle, Kenneth Christopher Thornton, Michael Peter Vanbrunt, Andrea Wang, Hengyu Xu
-
Publication number: 20140127209Abstract: The invention relates inter alia to a bivalent, bispecific construct comprising an anti-IL-6 antibody, or derivative thereof, and an anti-IL-23 antibody, or derivative thereof and its use in therapy. The invention also relates to useful anti-IL-6 antibodies and anti-IL-23 antibodies.Type: ApplicationFiled: March 8, 2013Publication date: May 8, 2014Inventors: Kenneth GRABSTEIN, William BRADY, Gordon KING, Natalie Winblade NAIRN, Kurt David SHANEBECK, Paul Heffner SLAGLE, Kenneth Christopher THORNTON, Michael Peter VANBRUNT, Andrea WANG, Hengyu XU
-
Patent number: 8568706Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.Type: GrantFiled: November 2, 2009Date of Patent: October 29, 2013Assignee: Allozyne, Inc.Inventors: Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn, Thomas James Graddis, Stephen McCraith, Deepshikha Datta
-
Patent number: 7829659Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.Type: GrantFiled: April 17, 2008Date of Patent: November 9, 2010Assignee: Allozyne, Inc.Inventors: Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn, Thomas James Graddis
-
Publication number: 20100254943Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.Type: ApplicationFiled: November 2, 2009Publication date: October 7, 2010Applicant: ALLOZYNE, INC.Inventors: Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn, Thomas James Graddis, Stephen McCraith, Deepshikha Datta
-
Patent number: 7632492Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.Type: GrantFiled: May 2, 2007Date of Patent: December 15, 2009Assignee: Allozyne, Inc.Inventors: Kenneth H. Grabstein, Andrea Wang, Natalie Winblade Nairn, Stephen McCraith, Deepshikha Datta
-
Publication number: 20080214439Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.Type: ApplicationFiled: April 17, 2008Publication date: September 4, 2008Applicant: ALLOZYNE, INC.Inventors: Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn, Thomas James Graddis
-
Publication number: 20080200641Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.Type: ApplicationFiled: April 17, 2008Publication date: August 21, 2008Applicant: ALLOZYNE, INC.Inventors: Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn, Thomas James Graddis
-
Publication number: 20080125347Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.Type: ApplicationFiled: May 2, 2007Publication date: May 29, 2008Applicant: ALLOZYNE, INC.Inventors: Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn